Nanoparticle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism

Journal of Nanobiotechnology

Volumn 9, Issue , 2011, Pages

  Sureban, Sripathi M ^a,b   May, Randal ^a,b   Mondalek, Fadee G ^d   Qu, Dongfeng ^a   Ponnurangam, Sivapriya ^d   Pantazis, Panayotis ^d   Anant, Shrikant ^f   Ramanujam, Rama P ^d,e   Houchen, Courtney W ^a,b,c  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c OU Cancer Institute   (United States)

^d Swaasth Inc   (United States)

^e ADNA Inc   (United States)

^f UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Cancer stem cells; DCAMKL 1; HCT116; MicroRNA; MiR 144; Nanoparticles; Notch signaling; SiRNA; Tumor xenograft

Indexed keywords

CANCER STEM CELLS; DCAMKL-1; HCT116; MICRORNAS; MIR-144; NOTCH SIGNALING; SIRNA; TUMOR XENOGRAFT;

BINDING SITES; BIOLOGICAL MATERIALS; DISEASES; DRUG DELIVERY; GENE ENCODING; NANOPARTICLES; PLANTS (BOTANY); POLYMERASE CHAIN REACTION; RNA; STEM CELLS; TRANSCRIPTION; TRANSCRIPTION FACTORS;

TUMORS;

ANTINEOPLASTIC AGENT; DCAMKL 1 ENZYME; GAMMA SECRETASE INHIBITOR; MESSENGER RNA; MICRORNA; NOTCH1 RECEPTOR; POLYGLACTIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; UNCLASSIFIED DRUG; DCLK1 PROTEIN, HUMAN; DIPEPTIDE; MIRN144 MICRORNA, HUMAN; MIRN200 MICRORNA, HUMAN; MIRNLET7 MICRORNA, HUMAN; MYC PROTEIN; MYC PROTEIN, HUMAN; N (N (3,5 DIFLUOROPHENACETYL)ALANYL)PHENYLGLYCINE TERT BUTYL ESTER; N-(N-(3,5-DIFLUOROPHENACETYL)ALANYL)PHENYLGLYCINE TERT-BUTYL ESTER; NANOPARTICLE; NOTCH1 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CANCER CONTROL; CANCER INHIBITION; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG MECHANISM; GENE EXPRESSION; IN VITRO STUDY; MALE; MOUSE; NANOENCAPSULATION; NANOTECHNOLOGY; NONHUMAN; ONCOGENE C MYC; TUMOR XENOGRAFT; ANIMAL; CARCINOMA; CELL STRAIN HCT116; COLORECTAL TUMOR; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; NUDE MOUSE; UPREGULATION;

GASTROPODA; MUS MUSCULUS;

ANIMALS; CARCINOMA; COLORECTAL NEOPLASMS; DIPEPTIDES; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, NUDE; MICRORNAS; NANOPARTICLES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, NOTCH1; TRANSCRIPTION FACTORS; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80052850129     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/1477-3155-9-40     Document Type: Article

References (56)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249. 10.3322/caac.20006, 19474385.
2. Potten CS, Booth C, Hargreaves D. The small intestine as a model for evaluating adult tissue stem cell drug targets. Cell Prolif 2003, 36:115-129. 10.1046/j.1365-2184.2003.00264.x, 12814429.
3. Sureban SM, May R, George RJ, Dieckgraefe BK, McLeod HL, Ramalingam S, Bishnupur KS, Natarajan G, Anant S, Houchen CW. Knockdown of RNA binding protein musashi-1 leads to tumor regression in vivo. Gastroenterology 2008, 134:1448-1458. 10.1053/j.gastro.2008.02.057, 18471519.
4. Okano H, Imai T, Okabe M. Musashi: a translational regulator of cell fate. J Cell Sci 2002, 115:1355-1359.
5. May R, Riehl TE, Hunt C, Sureban SM, Anant S, Houchen CW. Identification of a novel putative gastrointestinal stem cell and adenoma stem cell marker, doublecortin and CaM kinase-like-1, following radiation injury and in adenomatous polyposis coli/multiple intestinal neoplasia mice. Stem Cells 2008, 26:630-637. 10.1634/stemcells.2007-0621, 18055444.
6. May R, Sureban SM, Hoang N, Riehl TE, Lightfoot SA, Ramanujam R, Wyche JH, Anant S, Houchen CW. Doublecortin and CaM kinase-like-1 and leucine-rich-repeat-containing G-protein-coupled receptor mark quiescent and cycling intestinal stem cells, respectively. Stem Cells 2009, 27:2571-2579. 10.1002/stem.193, 3049723, 19676123.
7. May R, Sureban SM, Lightfoot SA, Hoskins AB, Brackett DJ, Postier RG, Ramanujam R, Rao CV, Wyche JH, Anant S, Houchen CW. Identification of a novel putative pancreatic stem/progenitor cell marker DCAMKL-1 in normal mouse pancreas. Am J Physiol Gastrointest Liver Physiol 2010, 299:G303-310. 10.1152/ajpgi.00146.2010, 2928534, 20522640.
8. Sureban SM, May R, Lightfoot SA, Hoskins AB, Lerner M, Brackett DJ, Postier RG, Ramanujam R, Mohammed A, Rao CV, et al. DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. Cancer Res 2011, 71:2328-2338. 10.1158/0008-5472.CAN-10-2738, 21285251.
9. Sureban SM, May R, Ramalingam S, Subramaniam D, Natarajan G, Anant S, Houchen CW. Selective blockade of DCAMKL-1 results in tumor growth arrest by a Let-7a MicroRNA-dependent mechanism. Gastroenterology 2009, 137:649-659. 659 e1-2, 10.1053/j.gastro.2009.05.004, 2775069, 19445940.
10. Huang C, Li M, Chen C, Yao Q. Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. Expert Opin Ther Targets 2008, 12:637-645. 10.1517/14728222.12.5.637, 18410245.
11. Singh SK. RNA interference and its therapeutic potential against HIV infection. Expert Opin Biol Ther 2008, 8:449-461. 10.1517/14712598.8.4.449, 18352849.
12. Xie FY, Woodle MC, Lu PY. Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Drug Discov Today 2006, 11:67-73. 10.1016/S1359-6446(05)03668-8, 16478693.
13. de Fougerolles AR. Delivery vehicles for small interfering RNA in vivo. Hum Gene Ther 2008, 19:125-132. 10.1089/hum.2008.928, 18257677.
14. Akhtar S, Benter IF. Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest 2007, 117:3623-3632. 10.1172/JCI33494, 2096447, 18060020.
15. Park J, Fong PM, Lu J, Russell KS, Booth CJ, Saltzman WM, Fahmy TM. PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomedicine 2009, 5:410-418. 10.1016/j.nano.2009.02.002, 2789916, 19341815.
16. Langer R, Folkman J. Polymers for the sustained release of proteins and other macromolecules. Nature 1976, 263:797-800. 10.1038/263797a0, 995197.
17. Visscher GE, Robison RL, Maulding HV, Fong JW, Pearson JE, Argentieri GJ. Biodegradation of and tissue reaction to 50:50 poly(DL-lactide-co-glycolide) microcapsules. J Biomed Mater Res 1985, 19:349-365. 10.1002/jbm.820190315, 4077887.
18. Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997, 28:5-24. 10.1016/S0169-409X(97)00048-3, 10837562.
19. Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 2000, 21:2475-2490. 10.1016/S0142-9612(00)00115-0, 11055295.
20. Lathia JD, Leodore L, Wheatley MA. Polymeric contrast agent with targeting potential. Ultrasonics 2004, 42:763-768. 10.1016/j.ultras.2003.12.018, 15047380.
21. Park YJ, Nah SH, Lee JY, Jeong JM, Chung JK, Lee MC, Yang VC, Lee SJ. Surface-modified poly(lactide-co-glycolide) nanospheres for targeted bone imaging with enhanced labeling and delivery of radioisotope. J Biomed Mater Res A 2003, 67:751-760.
22. Mondalek FG, Ashley RA, Roth CC, Kibar Y, Shakir N, Ihnat MA, Fung KM, Grady BP, Kropp BP, Lin HK. Enhanced angiogenesis of modified porcine small intestinal submucosa with hyaluronic acid-poly(lactide-co-glycolide) nanoparticles: From fabrication to preclinical validation. J Biomed Mater Res A 2010,
23. Sureban SM, Ramalingam S, Natarajan G, May R, Subramaniam D, Bishnupuri KS, Morrison AR, Dieckgraefe BK, Brackett DJ, Postier RG, et al. Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastrophe. Oncogene 2008, 27:4544-4556. 10.1038/onc.2008.97, 2677646, 18427544.
24. Leethanakul C, Patel V, Gillespie J, Pallente M, Ensley JF, Koontongkaew S, Liotta LA, Emmert-Buck M, Gutkind JS. Distinct pattern of expression of differentiation and growth-related genes in squamous cell carcinomas of the head and neck revealed by the use of laser capture microdissection and cDNA arrays. Oncogene 2000, 19:3220-3224. 10.1038/sj.onc.1203703, 10918578.
25. Rae FK, Stephenson SA, Nicol DL, Clements JA. Novel association of a diverse range of genes with renal cell carcinoma as identified by differential display. Int J Cancer 2000, 88:726-732. 10.1002/1097-0215(20001201)88:5<726::AID-IJC7>3.0.CO;2-H, 11072240.
26. Tohda S, Nara N. Expression of Notch1 and Jagged1 proteins in acute myeloid leukemia cells. Leuk Lymphoma 2001, 42:467-472. 10.3109/10428190109064603, 11699411.
27. Wang Z, Zhang Y, Li Y, Banerjee S, Liao J, Sarkar FH. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther 2006, 5:483-493.
28. Miyamoto Y, Maitra A, Ghosh B, Zechner U, Argani P, Iacobuzio-Donahue CA, Sriuranpong V, Iso T, Meszoely IM, Wolfe MS, et al. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 2003, 3:565-576. 10.1016/S1535-6108(03)00140-5, 12842085.
29. Fan X, Matsui W, Khaki L, Stearns D, Chun J, Li YM, Eberhart CG. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 2006, 66:7445-7452. 10.1158/0008-5472.CAN-06-0858, 16885340.
30. Katoh M. Notch signaling in gastrointestinal tract (review). Int J Oncol 2007, 30:247-251.
31. Schreck KC, Taylor P, Marchionni L, Gopalakrishnan V, Bar EE, Gaiano N, Eberhart CG. The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance. Clin Cancer Res 2010, 16:6060-6070. 10.1158/1078-0432.CCR-10-1624, 21169257.
32. Sang L, Roberts JM, Coller HA. Hijacking HES1: how tumors co-opt the anti-differentiation strategies of quiescent cells. Trends Mol Med 2010, 16:17-26. 10.1016/j.molmed.2009.11.001, 2864914, 20022559.
33. Turley EA, Veiseh M, Radisky DC, Bissell MJ. Mechanisms of disease: epithelial-mesenchymal transition--does cellular plasticity fuel neoplastic progression?. Nat Clin Pract Oncol 2008, 5:280-290. 2846172, 18349857.
34. Poste G, Greig R. On the genesis and regulation of cellular heterogeneity in malignant tumors. Invasion Metastasis 1982, 2:137-176.
35. Diehn M, Clarke MF. Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J Natl Cancer Inst 2006, 98:1755-1757. 10.1093/jnci/djj505, 17179471.
36. Polakis P. Wnt signaling and cancer. Genes Dev 2000, 14:1837-1851.
37. Zhang H, Li Y, Lai M. The microRNA network and tumor metastasis. Oncogene 2010, 29:937-948. 10.1038/onc.2009.406, 19935707.
38. Xia H, Ng SS, Jiang S, Cheung WK, Sze J, Bian XW, Kung HF, Lin MC. miR-200a-mediated downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion. Biochem Biophys Res Commun 2010, 391:535-541. 10.1016/j.bbrc.2009.11.093, 19931509.
39. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008, 283:14910-14914. 10.1074/jbc.C800074200, 18411277.
40. Herrero-Vanrell R, Ramirez L, Fernandez-Carballido A, Refojo MF. Biodegradable PLGA microspheres loaded with ganciclovir for intraocular administration. Encapsulation technique, in vitro release profiles, and sterilization process. Pharm Res 2000, 17:1323-1328. 10.1023/A:1026464124412, 11145241.
41. Garinot M, Fievez V, Pourcelle V, Stoffelbach F, des Rieux A, Plapied L, Theate I, Freichels H, Jerome C, Marchand-Brynaert J, et al. PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J Control Release 2007, 120:195-204. 10.1016/j.jconrel.2007.04.021, 17586081.
42. Wu Y, Wang W, Chen Y, Huang K, Shuai X, Chen Q, Li X, Lian G. The investigation of polymer-siRNA nanoparticle for gene therapy of gastric cancer in vitro. Int J Nanomedicine 2010, 5:129-136. 2841491, 20309399.
43. Chan JM, Valencia PM, Zhang L, Langer R, Farokhzad OC. Polymeric nanoparticles for drug delivery. Methods Mol Biol 2010, 624:163-175. 10.1007/978-1-60761-609-2_11, 20217595.
44. Mondalek FG, Ponnurangam S, Govind J, Houchen C, Anant S, Pantazis P, Ramanujam RP. Inhibition of angiogenesis- and inflammation-inducing factors in human colon cancer cells in vitro and in ovo by free and nanoparticle-encapsulated redox dye, DCPIP. J Nanobiotechnology 2010, 8:17. 10.1186/1477-3155-8-17, 2911398, 20633276.
45. Wang IJ, Jhuang MC, Chen YH, Yeh LK, Liu CY, Young TH. Chitosan modification of adenovirus to modify transfection efficiency in bovine corneal epithelial cells. PLoS one 2010, 5:e12085. 10.1371/journal.pone.0012085, 2919409, 20711466.
46. Godbey WT, Wu KK, Mikos AG. Size matters: molecular weight affects the efficiency of poly(ethylenimine) as a gene delivery vehicle. J Biomed Mater Res 1999, 45:268-275. 10.1002/(SICI)1097-4636(19990605)45:3<268::AID-JBM15>3.0.CO;2-Q, 10397985.
47. Patil Y, Panyam J. Polymeric nanoparticles for siRNA delivery and gene silencing. Int Journal Pharm 2009, 367:195-203.
48. Plentz R, Park JS, Rhim AD, Abravanel D, Hezel AF, Sharma SV, Gurumurthy S, Deshpande V, Kenific C, Settleman J, et al. Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 2009, 136:1741-1749. e1746, 10.1053/j.gastro.2009.01.008, 19208345.
49. Koch U, Radtke F. Notch and cancer: a double-edged sword. Cell Mol Life Sci 2007, 64:2746-2762. 10.1007/s00018-007-7164-1, 17687513.
50. Charafe-Jauffret E, Ginestier C, Birnbaum D. Breast cancer stem cells: tools and models to rely on. BMC Cancer 2009, 9:202. 10.1186/1471-2407-9-202, 2708191, 19555472.
51. Saad S, Stanners SR, Yong R, Tang O, Pollock CA. Notch mediated epithelial to mesenchymal transformation is associated with increased expression of the Snail transcription factor. Int J Biochem Cell Biol 2010, 42:1115-1122. 10.1016/j.biocel.2010.03.016, 20348013.
52. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297. 10.1016/S0092-8674(04)00045-5, 14744438.
53. McManus MT. MicroRNAs and cancer. Semin Cancer Biol 2003, 13:253-258. 10.1016/S1044-579X(03)00038-5, 14563119.
54. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004, 64:3753-3756. 10.1158/0008-5472.CAN-04-0637, 15172979.
55. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715. 10.1016/j.cell.2008.03.027, 2728032, 18485877.
56. Astete CE, Sabliov CM. Synthesis and characterization of PLGA nanoparticles. J Biomater Sci Polym Ed 2006, 17:247-289. 10.1163/156856206775997322, 16689015.